Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Biol Proced Online ; 26(1): 9, 2024 Apr 09.
Artículo en Inglés | MEDLINE | ID: mdl-38594619

RESUMEN

BACKGROUND: MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), original found in synthetic heroin, causes Parkinson's disease (PD) in human through its metabolite MPP+ by inhibiting complex I of mitochondrial respiratory chain in dopaminergic neurons. This study explored whether yeast internal NADH-quinone oxidoreductase (NDI1) has therapeutic effects in MPTP- induced PD models by functionally compensating for the impaired complex I. MPP+-treated SH-SY5Y cells and MPTP-treated mice were used as the PD cell culture and mouse models respectively. The recombinant NDI1 lentivirus was transduced into SH-SY5Y cells, or the recombinant NDI1 adeno-associated virus (rAAV5-NDI1) was injected into substantia nigra pars compacta (SNpc) of mice. RESULTS: The study in vitro showed NDI1 prevented MPP+-induced change in cell morphology and decreased cell viability, mitochondrial coupling efficiency, complex I-dependent oxygen consumption, and mitochondria-derived ATP. The study in vivo revealed that rAAV-NDI1 injection significantly improved the motor ability and exploration behavior of MPTP-induced PD mice. Accordingly, NDI1 notably improved dopaminergic neuron survival, reduced the inflammatory response, and significantly increased the dopamine content in striatum and complex I activity in substantia nigra. CONCLUSIONS: NDI1 compensates for the defective complex I in MPP+/MPTP-induced models, and vastly alleviates MPTP-induced toxic effect on dopaminergic neurons. Our study may provide a basis for gene therapy of sporadic PD with defective complex I caused by MPTP-like substance.

2.
Nanoscale ; 16(5): 2478-2489, 2024 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-38226534

RESUMEN

Incomplete recovery, baseline drift, and a long response time have been impeding the practical applications of transition metal dichalcogenide (TMD)-based gas sensors. Here, we report WS2 sensors with significantly improved gas recovery, rapid response, and negligible baseline drift by the incorporation of black phosphorus (BP) as well as the decoration of Pt to detect NO2 for the first time. Compared to bare WS2, the BP-WS2 sensors show higher sensitivity, better repeatability, and more excellent selectivity towards NO2 at the optimal operating temperature of 50 °C. Furthermore, the optimized 30%BP-WS2/Pt sensors exhibit a continuous enhancement in the recovery level and sensitivity with negligible baseline drift. The 30%BP-WS2/Pt sensor also exhibits a shorter response time of 28 s than 49.5 s for its counterpart WS2 sensor towards 32 ppm NO2. The enhanced sensing properties are primarily due to the combined effects of more adsorption sites provided by BP, the spill-over effect of Pt catalysis, and the WS2/BP heterostructure. Therefore, the Pt-decorated 30%BP-WS2 sensor exhibits prominent gas-sensing properties of high gas sensitivity, a low detection limit of 100 ppb, good selectivity, and fast response. Our strategy provides a new route for designing and optimizing TMD-based gas sensors with excellent gas-sensing performance.

3.
PeerJ ; 12: e17842, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39131609

RESUMEN

Background: Ferroptosis is a non-apoptotic iron-dependent form of cell death implicated in various cancer pathologies. However, its precise role in tumor growth and progression of cervical cancer (CC) remains unclear. Transferrin receptor protein 1 (TFRC), a key molecule associated with ferroptosis, has been identified as influencing a broad range of pathological processes in different cancers. However, the prognostic significance of TFRC in CC remains unclear. The present study utilized bioinformatics to explore the significance of the ferroptosis-related gene TFRC in the progression and prognosis of CC. Methods: We obtained RNA sequencing data and corresponding clinical information on patients with CC from The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx) and Gene Expression Omnibus (GEO) databases. Using least absolute shrinkage and selection operator (LASSO) Cox regression, we then generated a multigene signature of five ferroptosis-related genes (FRGs) for the prognostic prediction of CC. We investigated the relationship between TFRC gene expression and immune cell infiltration by employing single-sample GSEA (ssGSEA) analysis. The potential functional role of the TFRC gene was evaluated through gene set enrichment analysis (GSEA). Immunohistochemistry and qPCR was employed to assess TFRC mRNA and protein expression in 33 cases of cervical cancer. Furthermore, the relationship between TFRC mRNA expression and overall survival (OS) was investigated in patients. Results: CC samples had significantly higher TFRC gene expression levels than normal tissue samples. Higher TFRC gene expression levels were strongly associated with higher cancer T stages and OS events. The findings of multivariate analyses illustrated that the OS in CC patients with high TFRC expression is shorter than in patients with low TFRC expression. Significant increases were observed in the levels of TFRC mRNA and protein expression in patients diagnosed with CC. Conclusion: Increased TFRC expression in CC was associated with disease progression, an unfavorable prognosis, and dysregulated immune cell infiltration. In addition, it highlights ferroptosis as a promising therapeutic target for CC.


Asunto(s)
Ferroptosis , Receptores de Transferrina , Microambiente Tumoral , Neoplasias del Cuello Uterino , Humanos , Femenino , Ferroptosis/genética , Receptores de Transferrina/genética , Receptores de Transferrina/metabolismo , Neoplasias del Cuello Uterino/genética , Neoplasias del Cuello Uterino/inmunología , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/mortalidad , Microambiente Tumoral/inmunología , Microambiente Tumoral/genética , Pronóstico , Regulación Neoplásica de la Expresión Génica , Antígenos CD/genética , Persona de Mediana Edad , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo
4.
Diagn Pathol ; 19(1): 79, 2024 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-38863002

RESUMEN

BACKGROUND: Osteosarcoma is a bone tumor that is characterized by high malignancy and a high mortality rate, and that originates from primitive osteoblastic mesenchymal cells and is most common in rapidly growing long bones. PSMD14, also known as RPN11 or POH1, is a member of the JAMM isopeptidase family, which is able to remove the substrate protein ubiquitination label, thereby regulating the stability and function of the substrate protein. In this study, we explored the expression and potential biological significance of the PSMD14 deubiquitinating enzyme in osteosarcoma. METHODS: Immunohistochemical methods were used to detect the expression of PSMD14 in biopsies of 91 osteosarcoma patients, and the specimens were classified into high and low PSMD14 expression groups. The correlation between PSMD14 expression and clinical indicators and prognosis was compared.SiRNA was used to downregulate PSMD14 in two osteosarcoma cell lines (HOS and SJSA-1), and the effects of downregulation of PSMD14 on the viability, proliferation, and invasion ability of osteosarcoma cells were analyzed. RESULTS: We identified significant differences in recurrence, metastasis, and survival time of the osteosarcoma patients on the basis of PSMD14 expression. High expression of PSMD14 in osteosarcoma patients was associated with a low survival rate and high risk of metastasis and recurrence. Down-regulation of PSMD14 inhibited the viability, proliferation, and invasiveness of osteosarcoma cell lines. CONCLUSIONS: PSMD14 may be a new prognostic marker and therapeutic target for osteosarcoma.


Asunto(s)
Biomarcadores de Tumor , Neoplasias Óseas , Osteosarcoma , Osteosarcoma/patología , Osteosarcoma/mortalidad , Osteosarcoma/metabolismo , Osteosarcoma/genética , Humanos , Neoplasias Óseas/patología , Neoplasias Óseas/mortalidad , Neoplasias Óseas/metabolismo , Neoplasias Óseas/genética , Masculino , Biomarcadores de Tumor/metabolismo , Biomarcadores de Tumor/análisis , Femenino , Pronóstico , Línea Celular Tumoral , Adulto , Proliferación Celular , Complejo de la Endopetidasa Proteasomal/metabolismo , Adolescente , Adulto Joven , Persona de Mediana Edad , Invasividad Neoplásica , Transactivadores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA